Welcome to Blood Cancer Journal

Online * Open Access * Highest Quality Research

Blood Cancer Journal seeks to publish articles of the highest quality related to hematologic malignancies and related disorders. The Journal will consider for publication original research, reviews, guidelines and letters that are considered to be of high impact in the field.
Topics of particular interest include, but are not limited to, the following:

  • Preclinical studies of new compounds, especially those that provide mechanistic insights
  • Clinical trials and observations
  • Reviews related to new drugs and current management of hematologic malignancies
  • Novel observations related to new mutations, molecular pathways, and tumor genomics

Blood Cancer Journal recently received an Impact Factor of 6.126* — submit to Blood Cancer Journal and benefit from:

  • Wide visibility for your research through open access publication
  • Online submission and prompt publication times
  • Global exposure through nature.com to a wide audience

Download our author instructions (PDF, 304kB) to find out more.

Volume 7,
September 2017

ISSN (online): 2044-5385

2016 Impact Factor 6.126*
33/217 Oncology

Ayalew Tefferi
Vincent Rajkumar

*2016 Journal Citation Reports® Science Edition (Clarivate Analytics, 2017)

Not to be missed

Don’t miss out on these recently trending articles

Acute promyelocytic leukemia: where did we start, where are we now, and the future
APL has been transformed from the most fatal to the most curable form of acute leukemia in adults. The standard of care for low-risk patients no longer includes chemotherapy given the success of the phase 3 non-inferiority trial examining ATRA-ATO combination therapy. Regimens for treating high-risk APL have not been sufficiently compared to suggest superiority of one regimen over another.. Areas of ongoing need include efforts to decrease the early death rate, which is the primary cause for treatment failure, refinements in strategies for high-risk patients and a focus on survivorship care.

Chronic myelomonocytic leukemia in younger patients: molecular and cytogenetic predictors of survival and treatment outcome
In patients with chronic myelomonocytic leukemia (CMML), age>65 years is an adverse prognostic factor. This study analyses survival and treatment outcomes in 'young' adults with CMML. Survival in these patients, although higher than in older patients, is poor and is even worse in the setting of ASXL1 and SRSF2 mutations. These mutations, however, did not predict HMA response or impact transplant outcomes, suggesting that these treatments could erase the poor prognostic impact of these mutations in patients receiving only supportive care.

Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib
This phase 2 trial was designed to evaluate ixazomib, an orally bioavailable proteasome inhibitor, in patients with myeloma who have limited prior exposure to bortezomib. The study concludes that ixazomib has promising single-agent activity in relapsed myeloma along with a favorable toxicity profile. Addition of dexamethasone significantly enhances the response rates demonstrating an important role for this two-drug combination.

Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
This review compares major diagnostic criteria of the former WHO classifications for MPN and then focuses on details suggested for the upcoming revision of diagnostic guidelines. The proposed amendments regard not only newly discovered molecular markers, but also the introduction of so-called mPV including a lowering of Hb and Hct values and an upgrading of BM morphology as major criterion.


Thank you to our reviewers
We would like to thank all those who took the time to review for Blood Cancer Journal in 2014. The journal could not exist without the knowledge and critical evaluation that our reviewers provide. Your generosity is much appreciated, and we hope your association with the journal continues in future. Please click here for the full list of reviewers.

New Editors-in-Chief announced
Ayalew Tefferi and S. Vincent Rajkumar have been appointed as the new Editors-in-Chief of Blood Cancer Journal. Both have been involved with this journal since it was launched in 2011 and are looking forwards to raising its profile further following attainment of an Impact Factor of 6.126*
*2015 Journal Citation Reports® Science Edition (Thomson Reuters, 2016)

Extra navigation

23 September 2017

Sign up for e-alerts Web feed